Technologieangebote

Many modern computer applications use data compression methods like bzip2 or gzip. Those algorithms do not allow the processing of data in its compressed form,…

Die Erfindung beschreibt ein technisches Verfahren, nach welchem die Kombination zweier Halbleiterdetektoren, einer mit niedriger, einer mit hoher…

Die Sicherung von geschlossenen Räumen oder Wertgegenständen gegen Einbruch, Diebstahl oder Vandalismus ist eine zeitlose Aufgabe. Die eingesetzten Mittel…

The present invention relates to antibodies that exhibit a high affinity and specificity for the A1/B-domains of CEACAM1.

Commercial Opportunities…

The present invention relates to antibodies that exhibit a high affinity and specificity for the A1/B-domains of CEACAM1.

Commercial Opportunities
CEACAM1 is an adhesion receptor molecule implicated in growth regulation and the development of cancer. It belongs to the family of carcinoembryonic antigens which forms a part of the immunoglobulin superfamily (IgSF). CEACAMs play a central role with respect to cell adhesion, differentiation, activation, proliferation, morphogenesis and apoptosis as well as receptors for various pathogens (e. g. bacteria). CEACAMs are structurally closely related: they feature the function triggering N-domain and a C-domain consisting of A- and B-domains. Due to the structural similarity it is very challenging to obtain antibodies against specific CEACAM1-domains. CEACAM1 has been detected at elevated levels in the surrounding tissue of tumors and the tumors themselves. It appears that CEACAM1 is a suitable biomarker for the diagnosis and staging of tumors.

The present invention relates to antibodies that exhibit a high affinity and mono-specificity for the A1/B-domains of human CEACAM1. Thus, they are suitable to detect the membrane anchored, the cleaved soluble CEACAM1 and most of its derivatives and may be used in various in-vitro techniques in cancer research, e.g. ELISA, WB, IHC, fluorescence microscopy and flow cytometry.

The novel combination therapy, developed at the Julius-Maximilians-Universität Würzburg, is based on a combined treatment strategy using glucocorticoids…